Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Holdings Lowered by Teacher Retirement System of Texas

Teacher Retirement System of Texas lessened its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 9.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 14,862 shares of the specialty pharmaceutical company’s stock after selling 1,469 shares during the quarter. Teacher Retirement System of Texas’ holdings in Supernus Pharmaceuticals were worth $487,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in SUPN. Raiffeisen Bank International AG bought a new position in shares of Supernus Pharmaceuticals during the 4th quarter valued at about $25,000. Financial Management Professionals Inc. bought a new stake in shares of Supernus Pharmaceuticals in the 1st quarter worth approximately $30,000. Versant Capital Management Inc lifted its stake in Supernus Pharmaceuticals by 6,931.3% during the first quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company’s stock valued at $37,000 after purchasing an additional 1,109 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in Supernus Pharmaceuticals during the fourth quarter worth approximately $42,000. Finally, Mark Sheptoff Financial Planning LLC acquired a new position in Supernus Pharmaceuticals in the fourth quarter worth approximately $52,000.

Supernus Pharmaceuticals Stock Performance

NASDAQ SUPN opened at $33.52 on Thursday. The firm’s 50 day moving average price is $32.36 and its two-hundred day moving average price is $33.70. The stock has a market cap of $1.88 billion, a price-to-earnings ratio of 30.20 and a beta of 0.70. Supernus Pharmaceuticals, Inc. has a twelve month low of $27.05 and a twelve month high of $40.28.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, July 12th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.